Clinical Trials Browser

Renal Insufficiency × Lenalidomide × Clear all

Sleepiness, Arrhythmias, Cardiac, Cataract, Confusion, Coronary Artery Disease, Digestive System Diseases, Dizziness, Fatigue, Heart Failure, Hemorrhage, Hypersensitivity, Hypotension, Orthostatic, Hypothyroidism, Infections, Lymphoma, Peripheral Nervous System Diseases, Seizures, Thromboembolism, Tumor Lysis Syndrome, Neoplasms, Second Primary, Lung Diseases, Interstitial, Renal Insufficiency, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Teratogenesis

NCT04352205 2024-07-01

Daratumumab-Based Therapy for the Treatment of Newly Diagnosed Multiple Myeloma With Kidney Failure

Phase 2 Terminated

17 enrolled

Plasma cell

Multiple Myeloma, Renal Insufficiency

NCT05147493 2022-03-29

A Phase 2 Study of Isatuximab in Combination With Bortezomib, Cyclophosphamide and Dexamethasone Followed by Isatuximab and Lenalidomide Maintenance in Newly Diagnosed Patients With Multiple Myeloma and Severe Renal Impairment

Phase 2 Unknown

51 enrolled

Plasma cell

Blood Protein Disorders, Hematologic Diseases, Multiple Myeloma, Neoplasms, Neoplasms by Histologic Type, Paraproteinemias, Renal Insufficiency, Neoplasms, Plasma Cell

NCT01270932 2017-12-29

Lenalidomide & High Dose Dexamethasone for Untreated Multiple Myeloma Renal Failure Patients

Phase 2 Completed

28 enrolled

Plasma cell

Multiple Myeloma, Renal Insufficiency

NCT00779922 2016-10-11

Pharmacokinetics of Lenalidomide (Revlimid®) in Patients With Multiple Myeloma and Impaired Renal Function

Phase 2 Completed

39 enrolled

Plasma cell

Multiple Myeloma, Renal Insufficiency

Clinical Trials

Revlimid® Capsules Drug Use-results Surveillance (Relapsed or Refractory ATLL)

Daratumumab-Based Therapy for the Treatment of Newly Diagnosed Multiple Myeloma With Kidney Failure

A Phase 2 Study of Isatuximab in Combination With Bortezomib, Cyclophosphamide and Dexamethasone Followed by Isatuximab and Lenalidomide Maintenance in Newly Diagnosed Patients With Multiple Myeloma and Severe Renal Impairment

Lenalidomide & High Dose Dexamethasone for Untreated Multiple Myeloma Renal Failure Patients

Pharmacokinetics of Lenalidomide (Revlimid®) in Patients With Multiple Myeloma and Impaired Renal Function